Hemab Therapeutics Prices Upsized IPO at $18/Share, Raising $301.5M Ahead of Nasdaq Debut
feedReported by GlobeNewswire
Sentiment
Positive
Importance
9
Price
0
Mkt Cap
0
52W Low
0
52W High
0
Market data snapshot near publication time
summarizeSummary
Hemab Therapeutics Holdings, Inc. has priced its upsized initial public offering of 16,750,000 shares at $18.00 per share, generating gross proceeds of approximately $301.5 million. The offering was upsized, indicating strong investor demand for the clinical-stage biotechnology company. This significant capital infusion will support the development of its therapies for blood coagulation disorders. The company's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "COAG" on May 1, 2026. Traders will closely monitor the stock's performance as it makes its public market debut.
This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.